Enjaymo (sutimlimab-jome) led to clinically relevant reductions in fatigue and improvements in quality of life in adults with…
Articles by Marta Figueiredo, PhD
Long-term treatment with Sanofi’s Enjaymo (sutimlimab-jome) safely and effectively prevented red blood cell destruction (hemolysis), anemia, and the need…
Sanofi’s investigational therapy sutimlimab safely and rapidly prevents red blood cell destruction (hemolysis), increases hemoglobin levels, and reduces fatigue…
People with cold agglutinin disease (CAD) have significantly lower blood levels of C3 and C4 — two key molecules…
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of…
Researchers have reported a very rare case of cold agglutinin disease (CAD) associated with urothelial carcinoma, the most common type of…
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
The U.S. Food and Drug Administration (FDA) has issued a complete response to Sanofi’s application requesting that its…
Daratumumab, a therapy used to treat myeloma patients, effectively eased painful and disabling symptoms in a man with…
Erythropoietin (EPO) treatment safely promotes sustained increases in hemoglobin levels in people with cold agglutinin disease (CAD) and other…